GEN Exclusives

More »

GEN News Highlights

More »
Jun 25, 2007

Stem Cell Innovations and High Q to Develop Huntington's Disease Models

  • The High Q Foundation and Stem Cell Innovations (SCI) have entered into a two-year R&D alliance. The organizations will apply SCI's PluriCells™ to develop Huntington's-disease-specific human cell systems for the purpose of drug discovery.

    Under the terms of their agreement, SCI will receive up to $1.1 million from High Q upon completion of certain milestones. In addition, SCI has the right to further use, develop, and commercialize the outcome of the project.

    "This agreement will allow us to accelerate our efforts in generating a unique panel of human neurodegenerative disease models, which will be integral in the further development of our potential products," says SCI CEO, James Kelly.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?